Sign in to fuzzto save your conversations, follow your research and come back anytime.
Zydus Life Science
SectorHealthcare
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
In the news
Zydus Lifesciences USFDA inspection ends with 5 observations
Zydus-MSN Launch First Generic Adempas Tablets in US
Zydus Lifesciences hits 2-year high on strong growth outlook
Zydus Lifesciences hits 52-week high on USFDA compliance success
Zydus, Glenmark Lead Pharma Growth in August; Semaglutide Sales Rise
Zydus shares fall 1.46% despite positive EVIDENCES-X trial results
Macquarie Maintains Outperform Rating on Zydus Lifesciences
Zydus Lifesciences establishes treasury subsidiary in Gift City
Zydus Lifesciences shares rise on US FDA approval for Ascorbic Acid
Zydus Q1 FY27: Growth Over Profits
Zydus Life Dividend Ex-Date Tomorrow: Shares Drop 5th Session
Zydus-Apollo Shield MCD Partnership: India's Cancer Screening Revolution
Zydus-Sunshine JV: Strategic Cross-Border Pharma Play
Corporate Performance Drivers: RIL, ONGC, Ashok Leyland Lead Strategic Shifts
Corporate Buyback Strategies: Tax Reform Drives Capital Return Shift
Zydus Lifesciences: Capital Efficiency Through Buybacks and Strategic Acquisitions
The Quarter story
The two most recent quarterly results, compared side-by-side.
Revenue crosses ₹80,000 Cr in Q1 FY27 driven by dominant consumer brands, while margin compression and currency headwinds pressure profitability.
Consolidated revenue grew from ₹65,737 Cr to ₹80,170 Cr from Q1 FY26 to Q1 FY27, confirming strong top-line momentum
EBITDA margin fell from 33.7% to 24.1% from Q4 FY26 to Q1 FY27, showing profit compression
Gross margin improved from 72.8% to 74.0% from Q1 FY26 to Q4 FY26, reflecting robust cost management
North America sales share dropped from 49% to 10% from Q1 FY26 to Q1 FY27, signaling a major portfolio mix shift
Glucon-D and Sugar Free held market rank 1 from Q1 FY26 through Q1 FY27, maintaining unchallenged category leadership
Net debt climbed from -₹56,312 Cr to ₹43,050 Cr from Q1 FY26 to Q4 FY26, indicating rising leverage
R&D spending rose from ₹4,856 Cr to ₹6,982 Cr from Q1 FY26 to Q4 FY26, accelerating innovation pipeline execution
Net forex losses widened from -₹571 Cr to -₹6,449 Cr from Q1 FY26 to Q4 FY26, highlighting persistent currency headwinds
North America regulatory approvals increased from 6 to 9 from Q1 FY26 to Q4 FY26, expanding US market access
Other operating expenses rose from ₹13,648 Cr to ₹18,732 Cr from Q1 FY26 to Q4 FY26, pressuring bottom-line efficiency
Company insights, generated from the most recent coverage.
Two clean inspections inside one week — SEZ II manufacturing plus nil-observation New Jersey pharmacovigilance site — signals compliance depth across both plant and post-marketing systems, not just one good factory.
SEZ II Ahmedabad cGMP inspection (Sep 21-28, 2026) closed with just 1 observation and zero data-integrity findings — the absence of DI issues is what keeps import-alert and consent-decree risk off the table for this oral-solids export plant.
Clean SEZ II outcome lowers the approval hurdle for pending ANDAs sourced from that facility; with 63 ANDA approvals in a single FY, inspection hygiene is now the gating factor on launch cadence, not filing volume.